Eric C T Geijteman
Overview
Explore the profile of Eric C T Geijteman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sogaard M, Orskov M, Jensen M, Goedegebuur J, Kempers E, Visser C, et al.
J Thromb Haemost
. 2024 Oct;
23(1):190-200.
PMID: 39393778
Background: Despite uncertain benefit-risk profile near the end of life, antithrombotic therapy (ATT) is prevalent in patients with terminal cancer. Objectives: To examine adherence and persistence with ATT in terminally...
2.
Agema B, Vrielink K, Oomen-de Hoop E, van Tienen F, Geijteman E, van der Rijt C, et al.
J Pain Symptom Manage
. 2024 Aug;
68(6):e491-e499.
PMID: 39214260
Context: Subcutaneous (SC) administration of fentanyl allows for rapid dose titration to treat urgent cancer-related pain. After establishing the optimal fentanyl dose, patients typically rotate towards transdermal (TD) fentanyl patches....
3.
Elsten E, Pot I, Geijteman E, Hedman C, van der Heide A, van der Kuy P, et al.
J Pain Symptom Manage
. 2024 Aug;
68(5):443-455.e2.
PMID: 39094669
Context: Medications may become inappropriate for patients in the last phase of life and may even compromise their quality of life. Objective: To find consensus on recommendations regarding deprescribing of...
4.
Geijteman E, Kuip E, Oskam J, Lees D, Bruera E
BMJ
. 2024 Mar;
384:e076625.
PMID: 38428972
No abstract available.
5.
van Hylckama Vlieg M, Nasserinejad K, Visser C, Bramer W, Ashrani A, Bosson J, et al.
EClinicalMedicine
. 2023 Sep;
64:102194.
PMID: 37731937
Background: The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3-6 months and to continue anticoagulant...
6.
Antonisse A, van der Baan F, Grant M, Uyttewaal G, Verboeket C, Smits-Pelser H, et al.
BMC Prim Care
. 2023 Apr;
24(1):101.
PMID: 37061665
Background: Several preventive medications and supplements become inappropriate in the last phase of life due to increased risk of adverse events caused by changed pharmacokinetics, drug-drug interactions, and changed care...
7.
Geijteman E, Elsten E, van der Kuy P, van der Heide A, van der Rijt C, van Zuylen L
Ned Tijdschr Geneeskd
. 2021 Dec;
165.
PMID: 34854643
Patients with a limited life expectancy use many medications. Especially medications with a focus on the prevention and treatment of illnesses may be inappropriate in this last phase of life....
8.
van Esch H, van Zuylen L, Geijteman E, Oomen-de Hoop E, Huisman B, Noordzij-Nooteboom H, et al.
JAMA
. 2021 Oct;
326(13):1268-1276.
PMID: 34609452
Importance: Death rattle, defined as noisy breathing caused by the presence of mucus in the respiratory tract, is relatively common among dying patients. Although clinical guidelines recommend anticholinergic drugs to...
9.
Ham L, Geijteman E, Aarts M, Kuiper J, Kunst P, Raijmakers N, et al.
J Geriatr Oncol
. 2021 Aug;
13(1):53-59.
PMID: 34366274
Objectives: Medications at the end of life should be used for symptom control. Medications which potential adverse effects outweigh their expected benefits are called 'potentially inappropriate medications' (PIMs). PIMs are...
10.
Huisman B, Geijteman E, Arevalo J, Dees M, van Zuylen L, Szadek K, et al.
BMC Palliat Care
. 2021 Jul;
20(1):110.
PMID: 34271885
Background: Antithrombotics are frequently prescribed for patients with a limited life expectancy. In the last phase of life, when treatment is primarily focused on optimizing patients' quality of life, the...